What are the latest figures on the oral biologics & biosimilar drugs market’s size and projected CAGR?
The oral biologics & biosimilar drugs market size has grown rapidly in recent years. It will grow from $7.19 billion in 2024 to $8.6 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, growing awareness of oral biologics, increasing patent expirations, rising demand for biosimilars.
The oral biologics & biosimilar drugs market size is expected to see rapid growth in the next few years. It will grow to $15.11 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to targeted therapy, increasing focus on preventive medicine, rising healthcare spending, aging population. Major trends in the forecast period include advancements in oral delivery technology, orally administered biologics, biosimilar innovation, and patient-centric care.
Get Your Free Sample of The Global Oral Biologics & Biosimilar Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp
Which Market drivers have played a significant role in driving the oral biologics & biosimilar drugs market?
The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. For instance, in May 2023 According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the oral biologics & biosimilar drugs market growth.
What are the key segments within the oral biologics & biosimilar drugs market?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Order your report now for swift delivery
Which key players are shaping the oral biologics & biosimilar drugs market?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
How will emerging trends drive the oral biologics & biosimilar drugs market throughout the forecast period?
The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in April 2023, Eli Lilly and Company, a US-based that manufactures oral biologics and biosimilar drugs launched an insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr). For type 1 diabetes in adults, children, and infants, as well as type 2 diabetes in adults, insulin glargine products are used to improve glycemic control.
What are the major regional insights for the oral biologics & biosimilar drugs market, and which region holds the top position?
North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Oral Biologics & Biosimilar Drugs Market Report 2025 Offer?
The oral biologics & biosimilar drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A biosimilar refers to a medication that closely resembles a biological medication in both structure and function. A biological drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered ‘biosimilar’ if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
